Syringe-deliverable hydrogel expands soft-tissue protection platform for tendons and nerves
Alafair Biosciences Announces Launch of VersaCoat™ Flowable Hydrogel
3 min read Premium comments
launchAlafair BioscienceshydrogelVersaCoat Flowable Hydrogel
AUSTIN, Texas, June 30, 2026 /PRNewswire/ — Alafair Biosciences, a medical device company redefining soft-tissue protection in orthopedic surgery, today announced the launch of VersaCoat™ Flowable Hydrogel.
VersaCoat Flowable Hydrogel brings Alafair’s proprietary VersaCore™ Hydrogel Technology to an easy-to-use, syringe-deliverable format for delicate and difficult-to-access anatomy. The naturally-derived hyaluronic acid and alginate hydrogel provides a conformable, bioresorbable gliding interface that limits postoperative soft-tissue tethering in procedures involving tendons, ligaments, skeletal muscle, peripheral nerves, and the neural environment. By expanding soft-tissue protection beyond traditional sheet formats, VersaCoat Flowable Hydrogel gives surgeons an effective option for anatomically complex surgical sites where precise placement is desired.
“VersaCoat gives me another way to think about soft-tissue protection,” said Christopher Gross, MD, Orthopedic Foot & Ankle Surgeon. “I’ve had positive experiences with VersaWrap and have seen how effective soft-tissue protection can support more predictable recovery for my patients. VersaCoat adds the ability to bring better outcomes into cases where a sheet isn’t practical because of the anatomy or the amount of dissection required. VersaCoat gives me the freedom to address soft tissues that are layered, confined, or approximated.”
VersaCoat Flowable Hydrogel builds on the impressive market adoption of VersaWrap® Hydrogel Sheet, used in more than 40,000 implants across multiple specialties and healthcare systems. This established clinical experience provides a strong foundation for the introduction of VersaCoat Flowable Hydrogel as an additional soft-tissue protection option for surgeons.
“Alafair is defining the new standard for soft-tissue protection and expanding what’s possible for surgeons,” said Chris Sorensen, Chief Marketing Officer of Alafair Biosciences. “VersaCoat Flowable Hydrogel extends our differentiated approach to preventing postoperative soft-tissue tethering into an easy-to-use, collagen-free, and dye-free flowable format. Early commercial experience with VersaCoat exceeded our expectations, fueling momentum to scale adoption across a broader range of procedures.”
Alafair Biosciences, Inc. is an Austin-based medical device company focused on developing advanced biopolymer technologies for surgical soft-tissue protection. Its proprietary VersaCore™ Hydrogel Technology combines naturally-derived, high-molecular-weight hyaluronic acid and alginate to create conformable, bioresorbable devices that support healing tissues and maintain gliding surfaces during recovery. The company’s portfolio includes the VersaWrap® Hydrogel Sheet and VersaCoat™ Flowable Hydrogel, which are used in procedures involving tendons, peripheral nerves, ligaments, and skeletal muscle. Alafair’s mission is to redefine surgical healing with advanced biomaterials that prevent soft-tissue tethering, support natural mobility, and empower surgeons to help patients reclaim optimal physical function.
VersaWrap® Hydrogel Sheet (VersaWrap Tendon Protector, VersaWrap Nerve Protector) is a bioresorbable, hyaluronic acid and alginate-based soft-tissue protector that provides a conformable, non-constricting gliding layer in tendon and peripheral nerve procedures. VersaWrap is designed for a sutureless application, forming an ultrathin, uniform, tissue-adherent interface between adjacent tissue planes to allow mobility during early healing stages.
Developed from Alafair’s VersaCore™ Hydrogel Platform, VersaWrap established the clinical foundation for the company’s soft-tissue protection portfolio. The sheet form allows quick, easy placement on exposed anatomy in tendon, peripheral nerve, ligament, and skeletal muscle procedures. VersaWrap’s tissue-free composition avoids the variability associated with human- or animal-derived implants and may be placed adjacent to hardware and grafts where tissue gliding protection is desired.
VersaCoat™ Flowable Hydrogel (VersaCoat Tendon Protector, VersaCoat Nerve Protector) is a bioresorbable, hyaluronic acid and alginate-based soft-tissue protector engineered for precision delivery in anatomically complex procedures. VersaCoat forms a conformable, tissue-adherent hydrogel that stays where applied and creates a non-constricting, gliding interface between adjacent tissue planes. This interface reduces postoperative soft tissue tethering while allowing natural healing and mobility.
Developed from Alafair’s VersaCore™ Hydrogel Platform, VersaCoat builds upon the proven clinical foundation of the VersaWrap Hydrogel Sheet, expanding the platform’s utility to include flowable application for use on hard-to-reach anatomy with minimal mechanical manipulation of tissue. VersaCoat is indicated for use as a bioresorbable, flowable soft-tissue protector in tendon, peripheral nerve, ligament, and skeletal muscle procedures and is provided in a syringe-based format for rapid preparation and precise placement.
SOURCE Alafair Biosciences, Inc.
Why This Matters
Two Perspectives
MBA Lens: Economic and industry impact
Alafair Biosciences launched VersaCoat™ Flowable Hydrogel, expanding its soft-tissue protection platform. This syringe-deliverable product targets delicate and difficult-to-access anatomy, building on the market success of VersaWrap® Hydrogel Sheet, which has over 40,000 implants. The launch aims to scale adoption across a broader range of orthopedic procedures, redefining soft-tissue protection standards with a differentiated, easy-to-use format.
- VersaCoat™ expands Alafair's market reach by offering a flowable, syringe-deliverable hydrogel for complex anatomical sites, complementing its established sheet format.
- The company leverages strong market adoption of its VersaWrap® product to drive commercial momentum and scale the new hydrogel across various surgical specialties.
PhD Lens: Clinical and outcomes impact
Alafair Biosciences introduced VersaCoat™ Flowable Hydrogel, a syringe-deliverable, bioresorbable product based on VersaCore™ Hydrogel Technology. Composed of naturally-derived hyaluronic acid and alginate, it forms a conformable gliding interface. This hydrogel is designed to limit postoperative soft-tissue tethering in procedures involving tendons, ligaments, skeletal muscle, and peripheral nerves, supporting natural healing and mobility.
- The hydrogel utilizes a hyaluronic acid and alginate composition to create a bioresorbable, non-constricting gliding interface, preventing soft-tissue tethering.
- Its flowable, syringe-deliverable format allows precise application in anatomically complex surgical sites, building on established clinical experience from the VersaWrap® Hydrogel Sheet.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.